![](/img/cover-not-exists.png)
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer
Giuliani, Jacopo, Bonetti, AndreaJournal:
Journal of Oncology Pharmacy Practice
DOI:
10.1177/1078155220934531
Date:
June, 2020
File:
PDF, 223 KB
2020